Buy Combivent online
Generic name: Ipratropium/Salbutamol.
Active ingredient: ipratropium bromide and salbutamol sulfate (albuterol sulfate).
Combivent is a combined bronchodilating drug. Food and Drug Administration of USA have approved this drug for the treatment of the chronic obstructive diseases of the lungs. In the course of the numerous clinical studies of this drug it has been established that the pharmacological activity of the active components of Combivent does not cause severe side effects and thus it safely relieves the breathing of the patient and controls the course of the disease.
Buy Combivent Online
Combivent is a combined bronchodilating drug. Food and Drug Administration of USA have approved this drug for the treatment of the chronic obstructive diseases of the lungs. In the course of the numerous clinical studies of this drug it has been established that the pharmacological activity of the active components of Combivent does not cause severe side effects and thus it safely relieves the breathing of the patient and controls the course of the disease.
Combined bronchodilating medicine.
Ipratropium bromide blocks m-cholinergic receptors of plain muscles of tracheobronchial tree – mostly, large and medium bronchi, – suppresses reflectory bronchoconstriction, and decreases the secretion of respiratory tract’s mucous membrane gland.
With structural similarity to acetylcholine molecule, Ipratropium bromide is its competent antagonist. The drug effectively prevents the narrowing of bronchi that appears as a result of inhaling cigarette smoke, cold air, and because of various bronchospasm agents’ action, and eliminates spasm of bronchi associated with the influence of vagus nerve. The medicine almost doesn’t cause resorptive effect (weakly affects heart rate and arterial blood pressure – tachycardia requires the inhaling of at leaset 500 doses), only 10% of the drug achieves alveolus and small bronchi, while its remainders accumulate in the gullet or oral cavity and gets swallowed.
Salbutamol, in therapeutic doses causes evident stimulating action on beta-2-adrenoreceptors of bronchi, blood vessels, and myometrium. It almost doesn’t affect beta-1-adenoreceptors of the heart. The drug inhibits the release of histamine, leukotrienes, and PgD2 and other biologically active substances from mast cells during a long period. It reduces early and late bronchi reactivity.
Causes evident broncholytic effect, preventing or arresting bronchospasm, decreases airway resistance, increases lung vital capacity. Positively affects mucociliary clearance (increases it on 36% during chronic bronchitis), stimulates mucus secretion, activates ciliated epithelium functions. Has a wide variety of metabolic effects, such as reduction of K+ in plasma, affecting glycogenolysis and insulin emission, causing hyperglycemic (especially in patients with bronchial asthma) and steatolytic effect, and the increase of acidosis development risk. In recommended therapeutic doses, the drug doesn’t cause negative effect on cardiovascular system and doesn’t increase arterial blood pressure. In the least degree comparing to other medicines of this group causes positive chrono- and inotropic action. The medicine also causes the distention of coronary arteries.
Drug action
Combivent includes two active components – Salbutamol and Ipratropium – which provide a different mechanism of the action but have the same functions. Ipratropium bromide reduces the secretion of the mucous membrane glands of the respiratory tracts, and also effectively prevents the narrowing of bronchi appeared as a result of the inhalation of cigarette smoke, cool air, or action of different exogenous irritants. Salbutamol reduces early and late responsiveness of bronchi and provides the expressed broncholytic effect preventing or arresting bronchospasm, reduces the resistance in the respiratory tract. This component is able to stimulate the production of the mucus secretion in bronchi, influences on glycogenolysis and release of insulin. The combination of these two active components leads to the broad-spectrum action on the respiratory system in general. Due to this Combivent neutralizes all preconditions for the development of the chronic obstructive disease of the lungs at once and relieve the symptoms during the severe course of this disease.
Use of Combivent
Combivent is released in the form of the solution for aerosol. The use of aerosol for diseases of the respiratory system is the most effective way to improve breathing. The active particles of the medication get inside the lungs at once and start their activity. Due to this it is possible to reduce time before the onset of the action and improvement of the condition of the patient but it effectively increases the efficiency of the therapy.
- The initial dosage of Combivent is 2 doses 4 times a day.
- If the adequate effect is absent, the daily dose can be increased by two times.
- The length of the treatment is indicated individually by your attending doctor. If necessary this drug can be used on a regular basis.
Measures of precautions
Before taking the drug it is advisable to have a complete medical examination and find out the presence of the chronic disorder which may affect the action of the drug or worsen your condition.
- It is necessary to take the drug with caution in case of the chronic heart failure, arterial hypertension and other cardiovascular diseases as a patient may appear the symptoms of tachycardia, increase of the arterial pressure during the use of this medication
- It is not recommended to take Combivent during the ischemic disease of the heart, epilepsy, glaucoma, diabetes, and renal/hepatic failure. This medication will not cause the worsening of the symptoms of these diseases but it may indirectly affect the course of these chronic disorders.
- The use of this drug is contraindicated in case of the individual intolerance of Salbutamol or Ipratropium bromide and also during pregnancy.